Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Age Related Symptoms Clear all
Completed Phase 1 Interventional

FX-322 in Adults With Age-Related Sensorineural Hearing Loss

NCT04601909
View directory record Official record
Conditions
Presbycusis, Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
Interventions
FX-322, placebo
Drug · Other
Lead sponsor
Frequency Therapeutics
Industry
Eligibility
66 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Sarasota, Florida • Omaha, Nebraska • Amherst, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 28, 2026, 9:00 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users

NCT02945293
View directory record Official record
Conditions
Mild to Heavy Alcohol Consumption
Interventions
Oxycodone
Other
Lead sponsor
University of Washington
Other
Eligibility
35 Years and older
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 28, 2026, 9:00 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

NCT02214628
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Fovista® (anti-PDGF BB) plus anti-VEGF
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 28, 2026, 9:00 PM EDT
Not listed Not applicable Interventional

Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)

NCT03661034
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment, Memory Disorders, Memory Loss, Memory Impairment, Memory Disorders, Age Related, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia, Mild, Dementia, Alzheimer Type, Cognitive Decline
Interventions
GammaSense Stimulation System (non-invasive, non-significant risk)
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 28, 2026, 9:00 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

NCT01021956
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
STAKEL
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • West Columbia, South Carolina • Harlingen, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

NCT00304954
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 92 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 28, 2026, 9:00 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Synbiotic to Attenuate Resorption of the Skeleton

NCT06389539
View directory record Official record
Conditions
Osteoporosis, Inflammation, Aging
Interventions
SBD111 medical food, Placebo
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
60 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 4 Interventional Results available

Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration

NCT00473642
View directory record Official record
Conditions
Age-Related Maculopathy, Choroidal Neovascularization
Interventions
Ranibizumab, Verteporfin
Drug
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
50 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 1 Interventional

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

NCT01255462
View directory record Official record
Conditions
Advanced Age-related Macular Degeneration
Interventions
LFG316
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Not applicable Interventional Results available

Assessment of e-Audiology for Providing Clinical Services and Support

NCT04048460
View directory record Official record
Conditions
Hearing Loss, Age-Related, Presbycusis, Bilateral, Hearing Disability
Interventions
Delivery of hearing healthcare through eAudiology application
Device
Lead sponsor
University of South Florida
Other
Eligibility
70 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 28, 2026, 9:00 PM EDT
Active, not recruiting No phase listed Observational

Impact of Non-Exudative Type 1 MNV on AMD Progression

NCT06125977
View directory record Official record
Conditions
Age-Related Macular Degeneration, Neovascularization, Choroidal
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
73 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 28, 2026, 9:00 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

NCT03452527
View directory record Official record
Conditions
Choroidal Neovascularization, Wet Macular Degeneration
Interventions
ICON-1, aflibercept
Biological
Lead sponsor
Iconic Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Beverly Hills, California • Santa Ana, California • Syracuse, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 28, 2026, 9:00 PM EDT
Withdrawn No phase listed Observational

The Dose-Response Relationship of Rocuronium in Patients Taking Pyridostigmine

NCT02157545
View directory record Official record
Conditions
Muscle Relaxants
Interventions
Not listed
Lead sponsor
Shashi Bhatt, MD
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Sep 28, 2026, 9:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Taste Perception and Chronic Disease Risk

NCT01023906
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes, Obesity, Metabolic Syndrome, Aging
Interventions
Not listed
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 28, 2026, 9:00 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

NCT07496567
View directory record Official record
Conditions
Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Interventions
Tiespectus, Aflibercept
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
50 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
52
States / cities
Gilbert, Arizona • Encino, California • Mountain View, California + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 2 Interventional

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

NCT00426998
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Verteporfin, Bevacizumab
Drug
Lead sponsor
Retinal Consultants Medical Group
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Lamotrigine for Symptoms of Geriatric Bipolar Depression

NCT00621842
View directory record Official record
Conditions
Bipolar Disorder, Depression, Bipolar
Interventions
Lamotrigine regular tablet formulation, Lamotrigine novel formulation
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
White Plains, New York • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)

NCT00109564
View directory record Official record
Conditions
Age-Related Memory Disorders
Interventions
ispronicline (nicotinic acetylcholine receptor agonist)
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
15
States / cities
Mesa, Arizona • Peoria, Arizona • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2008 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT03256695
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol sulfate (ABS)
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
40 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
40
States / cities
Andalusia, Alabama • Anniston, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Musculoskeletal Effects of Bicarbonate

NCT01475214
View directory record Official record
Conditions
Muscle Loss, Fractures, Osteoporosis, Age Related, Fall Injury
Interventions
potassium bicarbonate, Inactive placebo capsule
Dietary Supplement · Other
Lead sponsor
Tufts University
Other
Eligibility
60 Years and older
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 28, 2026, 9:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Work-Related Effects of Heat, Activity, and Fat in Middle Aged Men

NCT02532725
View directory record Official record
Conditions
Obesity, Gender, Problem of Aging
Interventions
Cardiopulmonary Exercise Stress Test, Climatic-Controlled Cardiopulmonary Exercise Stress Test, Body Composition Evaluation, Pre-Exercise Risk Assessment
Procedure
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Other
Eligibility
35 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1972
U.S. locations
1
States / cities
Buckhannon, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 28, 2026, 9:00 PM EDT
Terminated Phase 1Phase 2 Interventional

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

NCT00712491
View directory record Official record
Conditions
Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
Sirolimus
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 28, 2026, 9:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamic Light Scattering Device (DLS) Study of Age-Related Changes in the Lens and Cataracts

NCT00007215
View directory record Official record
Conditions
Cataract, Healthy
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 1 Interventional

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

NCT03249740
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
GB-102, Aflibercept
Drug
Lead sponsor
Graybug Vision
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 28, 2026, 9:00 PM EDT